PUBLIC COMPANY
save$PCVXVaxcyte, Inc.
$PCVX58.27+3.66%San Carlos, CA, USupdated 17h ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 21Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
- phase3A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
- phase1A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
- phase3Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
- phase2A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
- phase2Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
- phase2Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
- phase2Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 7, 26SELLCowan Elvia· SVP, Finance & CAO−$180K↗
routine RSU / option mechanics (2)
- Apr 7, 26option exerciseCowan Elvia · SVP, Finance & CAO3,000 sh
- Apr 7, 26option exerciseCowan Elvia · SVP, Finance & CAO3,000 sh
🐶 Hiring Signal
next earnings Nov 3, 2026
Where Vaxcyte, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaInfectious Disease & Vaccines 41
News
no news has mentioned this company yet
Data sources
last refreshed 45m ago
Found something off?
comments(0)
5-min edit window · permanent after that